E vaping lung injury
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Search PubMed for recent e-vaping lung injury studies
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
E vaping lung injury
E-cigarette or vaping product use-associated lung injury (EVALI) is an acute/subacute respiratory illness linked to vaping. The 2019 outbreak in the US affected thousands, with vitamin E acetate (used as a diluent in THC-containing vape products) identified as the primary culprit. Symptoms include cough, dyspnea, fever, and GI complaints. Imaging typically shows bilateral ground-glass opacities. Treatment is supportive, often with corticosteroids.
Searching sources...
Searching PubMed
EVALI e-cigarette vaping associated lung injury
Finding Sources
Searching the Web
EVALI e-cigarette vaping lung injury 2024 2025 update
Now let me pull the textbook content and abstracts from the most important papers in parallel.
Reading File
Reading Article
PMID: 40427906
Reading Article
PMID: 36939271
Reading Article
PMID: 37458106
Here is a thorough overview of E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI), drawing from a pulmonology textbook and the latest peer-reviewed literature.
E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI)
Background & Epidemiology
EVALI emerged as a recognized clinical syndrome in mid-to-late 2019 when the CDC began receiving reports of acute lung injury in patients with a vaping history and no other identifiable cause. By January 2020, 2,668 hospitalized cases had been reported in the US, with 66% male and a median age of 24 years. More than 60 deaths were attributed to the outbreak. Youth (high school students) had e-cigarette use rates as high as 27.5% in 2019 (per the AHA Scientific Statement, Circulation 2023).
Causative Agent
The outbreak was traced primarily to vitamin E acetate, a cutting/diluent agent added to illicit THC-containing vape liquids:
-
84% of EVALI cases involved THC vaping; 33% used exclusively THC products
-
Bronchoalveolar lavage (BAL) samples from EVALI patients contained vitamin E acetate
-
Law enforcement seizures confirmed high proportions of illicit THC liquids with vitamin E acetate
-
Nicotine-only products were involved in a minority of cases; other toxic chemicals cannot be entirely ruled out
-
Murray & Nadel's Textbook of Respiratory Medicine, pp. 51-57
Pathophysiology
Vitamin E acetate is thought to interfere with normal surfactant function in the alveoli. Inhaled lipid-laden aerosols cause a toxic lipoid pneumonitis-like pattern. Proposed mechanisms include:
- Direct cytotoxic injury to type II pneumocytes
- Disruption of the pulmonary surfactant layer
- Activation of inflammatory cascades (innate immunity, oxidative stress)
- A range of histopathologic patterns has been reported: organizing pneumonia, diffuse alveolar damage, acute fibrinous pneumonitis, and lipoid pneumonia
Clinical Features
| Feature | Details |
|---|---|
| Symptoms | Cough, progressive dyspnea, fever, chills, myalgias, nausea/vomiting, diarrhea |
| Onset | Subacute (days to weeks after vaping) |
| Severity | Ranges from mild to fulminant ARDS requiring mechanical ventilation |
| Demographics | Young adults, predominantly male |
| History | Must ask specifically about THC vaping and informal/illicit product sources |
Diagnosis (Exclusion-Based)
There is no specific biomarker or test for EVALI. It is a diagnosis of exclusion:
- Use of e-cigarette/vaping product in the 90 days before symptom onset
- Pulmonary infiltrates on imaging (CXR or CT)
- No alternative plausible diagnosis (infection, malignancy, autoimmune disease)
Imaging findings:
- Bilateral, diffuse ground-glass opacities
- Subpleural sparing can be seen on CT
- Consolidation with air bronchograms in severe cases
BAL: Lipid-laden macrophages (oil red O staining positive) - a supportive but not pathognomonic finding
Management
- Stop all vaping immediately
- Corticosteroids: Anecdotally effective; hasten recovery in moderate-severe cases (methylprednisolone 0.5-1 mg/kg/day commonly used)
- Supportive care: Supplemental oxygen, bronchodilators, fluids
- ICU/mechanical ventilation for respiratory failure
- Screening for mental health and substance use disorders
- Counseling on nicotine cessation (varenicline, bupropion, NRT, behavioral support)
Current Status (2025-2026)
Following the 2019-2020 public health response and CDC warnings to remove vitamin E acetate from products, EVALI cases have declined significantly but persist at a low, endemic level. Key current concerns include:
- Underdiagnosis - symptom overlap with COVID-19, pneumonia, and other respiratory illness
- New vaping product formulations and devices continue to emerge
- The 2025 comprehensive review (Amjad et al., IJERPH 2025) highlights ongoing long-term repercussions and research gaps
- The umbrella + systematic review (Banks et al., MJA 2023) confirms conclusive evidence linking e-cigarettes to EVALI, particularly for THC/vitamin E acetate-containing products
Key Recent PubMed Evidence
| Evidence | Paper | PMID |
|---|---|---|
| Systematic Review (Tier 1) | Banks et al., 2023 - E-cigarettes and health outcomes: umbrella review of global evidence | 36939271 |
| AHA Scientific Statement | Rose et al., 2023 - Cardiopulmonary Impact of E-cigarettes (Circulation) | 37458106 |
| Comprehensive Review 2025 | Amjad et al., 2025 - EVALI: A Comprehensive Review (IJERPH) | 40427906 |
| Case Series 2024 | Tituana et al., 2024 - EVALI case review (Pneumologie) | 37857323 |
Clinical Takeaways
- Always ask about both nicotine and THC vaping in any young patient with unexplained respiratory illness
- Obtain detailed product history: what was vaped, where it was obtained (formal vs. informal/illicit)
- EVALI is a diagnosis of exclusion - rule out infection first
- Corticosteroids appear beneficial; evidence is observational
- All vaping should be stopped; counsel about cessation resources
- Long-term pulmonary sequelae after EVALI remain an active area of research
This is a shared conversation. Sign in to Orris to start your own chat.